Combined tACS Therapy for Mild Cognitive Impairment
Evaluation of a Cognitive Training Therapy Based on Synchronized Oscillatory Stimulation in Patients With Mild Cognitive Impairment Through a Randomized Clinical Trial
This study is testing whether combining brain stimulation with memory exercises can help people with Mild Cognitive Impairment improve their memory and slow down cognitive decline.
Quick facts
| Phase | Phase 2 |
|---|---|
| Study type | Interventional |
| Enrollment | 62 (estimated) |
| Ages | 60 Years and up |
| Sex | All |
| Sponsor | Universidad del Desarrollo Academic / other |
| Locations | 1 site (Valparaíso, Quinta Región) |
| Trial ID | NCT05291208 on ClinicalTrials.gov |
What this trial studies
This clinical trial aims to enhance working memory in patients with Mild Cognitive Impairment (MCI) by combining cognitive training with non-invasive brain stimulation using transcranial alternating current stimulation (tACS). The intervention targets the critical stage of MCI, which is often a precursor to dementia, by leveraging neuroplasticity to improve cognitive functions. Participants will undergo a structured program that integrates both cognitive exercises and tACS to potentially delay the progression of cognitive decline. The study is designed to assess the efficacy of this combined approach compared to traditional cognitive training alone.
Who should consider this trial
Good fit: Ideal candidates for this study are individuals aged 60 and older who have been diagnosed with Mild Cognitive Impairment and have completed at least six years of schooling.
Not a fit: Patients with other neurodegenerative diseases, significant psychiatric conditions, or a history of epilepsy may not benefit from this study.
Why it matters
Potential benefit: If successful, this intervention could help maintain cognitive function and improve quality of life for patients with Mild Cognitive Impairment.
How similar studies have performed: Other studies have shown promising results with similar non-pharmacological interventions for cognitive enhancement in MCI, suggesting potential for success in this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age equal to or greater than 60 years. * Presence of Mild Cognitive Impairment, according to the diagnostic criteria established in Petersen et al. (2014). * Have six or more years of complete schooling (presence of reading and writing). Exclusion Criteria: * The previous diagnosis of other neurodegenerative diseases. * Attending another cognitive training program. * History of Epilepsy or current presence of epileptic seizures. * Presence of psychiatric diseases. * Presence of a relevant depressive picture (GDS \>=2). * History of important neurological alterations such as the history of stroke, transient ischemic attack, cranial brain trauma. Important alterations of communication.
Where this trial is running
Valparaíso, Quinta Región
- Centro de Investigación del Desarrollo de Cognición y Lenguaje, Faculty of Medicine, Universidad de Valparaíso. — Valparaíso, Quinta Región, Chile (Recruiting)
Study contacts
- Principal investigator: Pablo Billeke, PhD — Social Neuroscience and Neuromodulation Laboratory Director
- Study coordinator: Begoña Gongora, PhD
- Email: begona.gongora@uv.cl
- Phone: +56 9 9438 5688
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.